Tags

Type your tag names separated by a space and hit enter

Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
Clin Infect Dis. 2005 Jan 15; 40(2):303-5.CI

Abstract

Tolerability of the combination of zidovudine-lamivudine and lopinavir-ritonavir as postexposure prophylaxis (PEP) for human immunodeficiency virus infection was prospectively assessed. A total of 121 patients were enrolled in the study; 23 patients discontinued PEP prematurely for reasons other than adverse events. Of the other 98 patients, 58 (59%) experienced adverse effects, which led to premature PEP discontinuation in 20 cases (20%).

Authors+Show Affiliations

Centre d'Information et de Soins sur l'Immunodeficience Humaine, Lorraine Champagne-Ardenne, France. Christian.Rabaud@wanadoo.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15655751

Citation

Rabaud, Christian, et al. "Tolerability of Postexposure Prophylaxis With the Combination of Zidovudine-lamivudine and Lopinavir-ritonavir for HIV Infection." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 40, no. 2, 2005, pp. 303-5.
Rabaud C, Burty C, Grandidier M, et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis. 2005;40(2):303-5.
Rabaud, C., Burty, C., Grandidier, M., Christian, B., Penalba, C., Béguinot, I., Jeanmaire, H., & May, T. (2005). Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 40(2), 303-5.
Rabaud C, et al. Tolerability of Postexposure Prophylaxis With the Combination of Zidovudine-lamivudine and Lopinavir-ritonavir for HIV Infection. Clin Infect Dis. 2005 Jan 15;40(2):303-5. PubMed PMID: 15655751.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. AU - Rabaud,Christian, AU - Burty,Christine, AU - Grandidier,Michel, AU - Christian,Bernard, AU - Penalba,Christian, AU - Béguinot,Isabelle, AU - Jeanmaire,Henri, AU - May,Thierry, Y1 - 2004/12/21/ PY - 2004/06/03/received PY - 2004/09/01/accepted PY - 2005/1/19/pubmed PY - 2006/6/2/medline PY - 2005/1/19/entrez SP - 303 EP - 5 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 40 IS - 2 N2 - Tolerability of the combination of zidovudine-lamivudine and lopinavir-ritonavir as postexposure prophylaxis (PEP) for human immunodeficiency virus infection was prospectively assessed. A total of 121 patients were enrolled in the study; 23 patients discontinued PEP prematurely for reasons other than adverse events. Of the other 98 patients, 58 (59%) experienced adverse effects, which led to premature PEP discontinuation in 20 cases (20%). SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/15655751/Tolerability_of_postexposure_prophylaxis_with_the_combination_of_zidovudine_lamivudine_and_lopinavir_ritonavir_for_HIV_infection_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/426589 DB - PRIME DP - Unbound Medicine ER -